Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Sood A, Duseja A, Kabrawala M, Amrose P, Goswami B, Chowdhury A, Sarin SK, Koshy A, Hyland RH, Lu S, Camus G, Stamm LM, Brainard DM, Subramanian GM, Prasad M, Bhatia S, Shah SR, Kapoor D, Shalimar, Saraswat V. Sood A, et al. Among authors: subramanian gm. Hepatol Int. 2019 Mar;13(2):173-179. doi: 10.1007/s12072-019-09927-6. Epub 2019 Feb 21. Hepatol Int. 2019. PMID: 30790229 Free PMC article. Clinical Trial.
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Younossi ZM, Stepanova M, Estep M, Negro F, Clark PJ, Hunt S, Song Q, Paulson M, Stamm LM, Brainard DM, Subramanian GM, McHutchison JG, Patel K. Younossi ZM, et al. Among authors: subramanian gm. J Hepatol. 2016 Jan;64(1):29-36. doi: 10.1016/j.jhep.2015.08.027. Epub 2015 Sep 1. J Hepatol. 2016. PMID: 26341824
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP. Bourlière M, et al. Among authors: subramanian gm. Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31. Lancet Gastroenterol Hepatol. 2018. PMID: 29859740 Clinical Trial.
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Zeuzem S, et al. Among authors: subramanian gm. N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795201 Free article. Clinical Trial.
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Grebely J, et al. Among authors: subramanian gm. Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23. Clin Infect Dis. 2016. PMID: 27553377 Free PMC article. Clinical Trial.
Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes.
Shah SR, Rao PN, Sarin SK, Chowdhury A, Bhatia S, Dharamsi R, Goswami BD, Kapoor D, Luaia R, Mehta R, Mukewar S, Prasad VG, Rai RR, Saigal S, Singh D, Trehanpati N, Chen S, Gaggar A, Knox SJ, Subramanian GM, Singh SP, Sood A, Varghese J, Venugopal RV. Shah SR, et al. Among authors: subramanian gm. Indian J Gastroenterol. 2016 Nov;35(6):469-477. doi: 10.1007/s12664-016-0709-1. Epub 2016 Nov 15. Indian J Gastroenterol. 2016. PMID: 27844277
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Jacobson IM, et al. Among authors: subramanian gm. Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5. Gastroenterology. 2017. PMID: 28390869 Clinical Trial.
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Bourlière M, et al. Among authors: subramanian gm. N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512. N Engl J Med. 2017. PMID: 28564569 Free article. Clinical Trial.
150 results